An interventional study of Aerobic Exercise and Combined Aerobic and Resistance Exercise in Lymphoma, Physical Exercise and Cardiotoxicity, sponsored by Norwegian School of Sport Sciences. Recruiting at 2 sites in 2 countries. Open to participants aged 20 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-22.
Sponsored by Norwegian School of Sport Sciences · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Lymphoma with a site in Norway — 2 open to participants now, 5 under way, 1 of them phase 3. Lymphoma · Norway.
Among the 20 studies in Lymphoma with a site in Norway, this one is the 9th largest by planned enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2024, is one of 6 with no phase, and was the 18th registered.
3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.
Browse Lymphoma studies →2 of the 20 studies in Lymphoma with a site in Norway are open now. Recruiting first, the newest first:
University of Oslo · Sites in Norway
Ages 18–80
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 20 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 7
First in 1993; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 280 is above the median of 43 across 2,320 interventional studies indexed under Lymphoma.
Median enrollment 200 across the 19 interventional studies, 13 across the 1 observational. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 20 have an industry lead sponsor. The 10 most frequent:
Norwegian School of Sport Sciences is the lead sponsor of 46 studies on the registry; 6 are open to participants now.
Norwegian School of Sport Sciences has 1 study filed under Lymphoma — fewer than ten, so there is no comparison to draw.
2 of the studies in Lymphoma with a site in Norway that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06356129Phase 3CelgeneStudy to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma | 2027-08-09 |
| NCT06645093University of OsloFeasibility of Intermittent Fasting During Chemotherapy | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Lymphoma with a site in Norway, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to compare the effects of aerobic exercise with or without addition of resistance exercise to usual care in individuals treated with anthracyclines for lymphomas and to compare exercise effects to age- and sex-matched individuals with no prior history of malignant diseases.
In this study, a comparison of the exercise effects between individuals previously treated for specific lymphoma diagnoses and individuals with no history of cancer will be conducted. Therefore, in addition to a randomized controlled trial in individuals with a previous lymphoma diagnosis (i.e., exercise groups and a non-exercising control group), a reference group comprising age- and sex-matched individuals with no history of a cancer diagnosis will also be included. Participants in the reference group will undergo the same exercise intervention as the aerobic exercise group. This study recruits through invitation only.
The primary endpoint in this study is the change in cardiorespiratory fitness, assessed as VO2peak. Secondary endpoints include common risk factors for cardiovascular disease and cardiometabolic health, other variables derived from the cardiopulmonary exercise test and lung function assessments, and muscle cellular endpoints from muscle biopsies obtained from m. vastus lateralis, in addition to patient-reported outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion Criteria Lymphoma participants and non-cancer reference group:
Exclusion Criteria Lymphoma participants:
Exclusion Criteria Lymphoma participants and non-cancer reference group:
Aerobic Exercise twice weekly for 5 months.
Behavioral: Aerobic Exercise
Combined Aerobic and Resistance Exercise twice weekly for 5 months.
Behavioral: Combined Aerobic and Resistance Exercise
Standard Care, i.e no exercise intervention.
Aerobic Exercise twice weekly for 5 months.
Behavioral: Aerobic Exercise
Participants receive twice weekly supervised aerobic treadmill-based exercise sessions for five months. Session duration varies from 20 to 60 minutes, including warm-up, with exercise intensity ranging from 60 to 95% of peak heart rate. Maximal exercise capacity (VO2peak and peak heart rate) will be determined by the CPET performed by certified exercise physiologists at baseline.The exercise prescription will be sequenced so that the exercise intensity and -duration of each exercise varies within each week, leading to an accumulative increase in weekly exercise volume throughout the intervention. This intervention is also given to the Active Comparator group (i.e. non-cancer reference group)
Twice weekly, supervised combined aerobic and resistance exercise sessions will be offered to participants. Participants randomized to the combined aerobic and resistance training group will follow the same aerobic exercise prescription as described for the Aerobic Exercise arm. In addition, participants in this group will perform five resistance exercises after the aerobic sessions. The resistance exercises will be leg press, knee extension, and calf rise, followed by seated row and chest press. Following familiarization, the training load will progressively increase following a linear periodization model throughout the intervention. exercise prescription will be sequenced so that the exercise intensity and -duration of each exercise varies within each week, leading to an accumulative increase in weekly exercise volume throughout the intervention. Only Lymphoma participants can be randomized to this arm.
VO2peak
Peak oxygen uptake during a treadmill-based cardiopulmonary exercise test
Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Systolic- and diastolic heart chamber dimensions
Cardiac morphology and function will be assessed by echocardiography (2D and 3D echocardiography and 2D strain echocardiography)
Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Systolic- and diastolic longitudinal strain
Cardiac morphology and function will be assessed by echocardiography (2D and 3D echocardiography and 2D strain echocardiography)
Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Lean body mass
Body composition will be assessed by dual x-ray absorptiometry
Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Fat mass
Body composition will be assessed by dual x-ray absorptiometry
Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Forced Vital Capacity
Lung function are assessed with spirometry.
Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Forced Expiratory Volume 1 sec
Lung function are assessed with spirometry.
Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Maximal voluntary ventilation
Lung function are assessed with spirometry.
Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Diffusion capacity
Diffusion capacity for carbon monoxide is assessed with single breath diffusion capacity test.
Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Physical activity
Actigraph accelerometer with physical activity diary. 7 days consecutive measurement at each timepoints.
Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Physical activity
Patient reported physical activity is assessed with Godin Leisure-Time Exercise Questionnaire
Time frame: Baseline, 10-12 weeks from baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Global Health related Quality of life
Patient reported health related quality of life will be assessed with EORTC QLQ C 30
Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Blood volume
Will be assessed in Norway only. Using the carbon monoxide rebreathing method.
Time frame: Baseline, five months from baseline (i.e. end of intervention) and 2 years from baseline
Muscle fiber area
Will be assessed in Norway only. Change in muscle morphology will be assessed in muscle biopsies using immunohistochemistry
Time frame: Baseline, five months from baseline (i.e. end of intervention)
Muscle fiber type
Will be assessed in Norway only. Change in muscle morphology will be assessed in muscle biopsies using immunohistochemistry
Time frame: Baseline, five months from baseline (i.e. end of intervention)
Muscle mitochondria mass
Will be assessed in Norway only. Change in mitochondrial proteins will be assessed in muscle biopsies using western blot
Time frame: Baseline, five months from baseline (i.e. end of intervention)
Muscle genome-wide DNA methylation and gene expression
Will be assessed in Norway only. For a sub-group of participants, muscle biopsies will be further processed for RNA and DNA
Time frame: Baseline, five months from baseline (i.e. end of intervention)
Adverse events
Medical records and Patient reported outcome version of the Common Terminology Criteria for Adverse Events.
Time frame: Five months from baseline (i.e. end of intervention)
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Sep 2028, 53 months after the start.
Of 161 non-industry interventional studies with no phase under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 87. This study's planned 53 months is above that.
Counting every sponsor, half of 170 studies reached it within 43 months; a quarter within 23 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Norwegian School of Sport Sciences